What every intensivist should know about Tocilizumab

Given its unknown biological specifics in the critical care context, we have analyzed the longitudinal course of IL-6, together with C-reactive protein (CRP), procalcitonin (PCT) and leucocyte counts in 16 COVID-19 patients (Fig. 1). Tocilizumab was almost exclusively administered if there was a progression of the disease (i.e., requirement of invasive ventilation in those on high-flow oxygen or deterioration in invasively ventilated patients) despite prior steroid use. Risk of serious infections in tocilizumab versus other biologic drugs in patients with rheumatoid arthritis: a multidatabase cohort study.